Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Jason Ahee, M.D.

Status and phase: Not yet enrolling; Phase 3; Phase 2

Conditions: Endophthalmitis

Treatments: Drug: Moxifloxacin; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03244072

PIND 134134

Details and patient eligibility

About

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Full description

Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

Enrollment: 60,000 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• visually significant cataracts

Exclusion criteria

• allergy to fluoroquinolones, cobalamin (B12)

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60,000 participants in 2 patient groups, including a placebo group

Treatment group

Active Comparator group

Description:

Intracameral injection of moxifloxacin solution after cataract surgery

Treatment:

Drug: Moxifloxacin

Placebo group

Placebo Comparator group

Description:

Intracameral injection of placebo after cataract surgery

Treatment:

Drug: Placebo